TY  - JOUR
AU  - Tomić, Tanja
AU  - Henman, Martin
AU  - Tadić, Ivana
AU  - Antić-Stanković, Jelena
AU  - Santric Milicević, Milena
AU  - Maksimović, Nataša
AU  - Odalović, Marina
PY  - 2023
UR  - https://farfar.pharmacy.bg.ac.rs/handle/123456789/4832
AB  - Background In Europe, Serbia occupies a high position in antibiotic utilization and antimicrobial resistance (AMR). Aim The aim was to analyse utilization trends of meropenem, ceftazidime, aminoglycosides, piperacillin/tazobactam and fluoroquinolones (2006–2020), and the reported AMR in Pseudomonas aeruginosa (2013–2020) in Serbia and to compare with data from eight European countries (2015–2020). Method Joinpoint regression was used to analyse antibiotic utilization data (2006–2020) and the reported AMR in Pseu- domonas aeruginosa (2013–2020). Data sources were relevant national and international institutions. Antibiotic utilization and AMR in Pseudomonas aeruginosa data in Serbia were compared with eight European countries. Results There was a significantly increased trend for ceftazidime utilization and reported resistance in Pseudomonas aer- uginosa, Serbia (p < 0.05) (2018–2020). For ceftazidime, piperacillin/tazobactam, and fluoroquinolones resistances in Pseu- domonas aeruginosa an increased trend was observed, Serbia (2013–2020). A decrease in both the utilization of aminogly- cosides, Serbia (p < 0.05) (2006–2018) and contemporaneous Pseudomonas aeruginosa resistance (p > 0.05) was detected. Fluoroquinolone utilization (2015–2020) was highest in Serbia compared to Netherlands and Finland, 310 and 305% higher, similar compared to Romania, and 2% less compared to Montenegro. Aminoglycosides (2015–2020) were 2550 and 783% more used in Serbia compared to Finland and Netherlands, and 38% less regarding Montenegro. The highest percentage of Pseudomonas aeruginosa resistance was in Romania and Serbia (2015–2020). Conclusion The use of piperacillin/tazobactam, ceftazidime and fluoroquinolones should be carefully monitored in clinical practice due to increased Pseudomonas aeruginosa resistance. The level of utilization and AMR in Pseudomonas aeruginosa is still high in Serbia compared to other European countries.
PB  - Springer
T2  - International Journal of Clinical Pharmacy
T1  - Antimicrobial utilization and resistance in Pseudomonas aeruginosa using segmented regression analysis: a comparative study between Serbia and eight European Countries
DO  - 10.1007/s11096-023-01603-y
ER  - 

@article{
author = "Tomić, Tanja and Henman, Martin and Tadić, Ivana and Antić-Stanković, Jelena and Santric Milicević, Milena and Maksimović, Nataša and Odalović, Marina",
year = "2023",
abstract = "Background In Europe, Serbia occupies a high position in antibiotic utilization and antimicrobial resistance (AMR). Aim The aim was to analyse utilization trends of meropenem, ceftazidime, aminoglycosides, piperacillin/tazobactam and fluoroquinolones (2006–2020), and the reported AMR in Pseudomonas aeruginosa (2013–2020) in Serbia and to compare with data from eight European countries (2015–2020). Method Joinpoint regression was used to analyse antibiotic utilization data (2006–2020) and the reported AMR in Pseu- domonas aeruginosa (2013–2020). Data sources were relevant national and international institutions. Antibiotic utilization and AMR in Pseudomonas aeruginosa data in Serbia were compared with eight European countries. Results There was a significantly increased trend for ceftazidime utilization and reported resistance in Pseudomonas aer- uginosa, Serbia (p < 0.05) (2018–2020). For ceftazidime, piperacillin/tazobactam, and fluoroquinolones resistances in Pseu- domonas aeruginosa an increased trend was observed, Serbia (2013–2020). A decrease in both the utilization of aminogly- cosides, Serbia (p < 0.05) (2006–2018) and contemporaneous Pseudomonas aeruginosa resistance (p > 0.05) was detected. Fluoroquinolone utilization (2015–2020) was highest in Serbia compared to Netherlands and Finland, 310 and 305% higher, similar compared to Romania, and 2% less compared to Montenegro. Aminoglycosides (2015–2020) were 2550 and 783% more used in Serbia compared to Finland and Netherlands, and 38% less regarding Montenegro. The highest percentage of Pseudomonas aeruginosa resistance was in Romania and Serbia (2015–2020). Conclusion The use of piperacillin/tazobactam, ceftazidime and fluoroquinolones should be carefully monitored in clinical practice due to increased Pseudomonas aeruginosa resistance. The level of utilization and AMR in Pseudomonas aeruginosa is still high in Serbia compared to other European countries.",
publisher = "Springer",
journal = "International Journal of Clinical Pharmacy",
title = "Antimicrobial utilization and resistance in Pseudomonas aeruginosa using segmented regression analysis: a comparative study between Serbia and eight European Countries",
doi = "10.1007/s11096-023-01603-y"
}

Tomić, T., Henman, M., Tadić, I., Antić-Stanković, J., Santric Milicević, M., Maksimović, N.,& Odalović, M.. (2023). Antimicrobial utilization and resistance in Pseudomonas aeruginosa using segmented regression analysis: a comparative study between Serbia and eight European Countries. in International Journal of Clinical Pharmacy
Springer..
https://doi.org/10.1007/s11096-023-01603-y

Tomić T, Henman M, Tadić I, Antić-Stanković J, Santric Milicević M, Maksimović N, Odalović M. Antimicrobial utilization and resistance in Pseudomonas aeruginosa using segmented regression analysis: a comparative study between Serbia and eight European Countries. in International Journal of Clinical Pharmacy. 2023;.
doi:10.1007/s11096-023-01603-y .

Tomić, Tanja, Henman, Martin, Tadić, Ivana, Antić-Stanković, Jelena, Santric Milicević, Milena, Maksimović, Nataša, Odalović, Marina, "Antimicrobial utilization and resistance in Pseudomonas aeruginosa using segmented regression analysis: a comparative study between Serbia and eight European Countries" in International Journal of Clinical Pharmacy (2023),
https://doi.org/10.1007/s11096-023-01603-y . .